Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Compare
Compare
Traded in other countries / regions
GILD.USA0QYQ.UKGIS.GermanyGILD.MexicoGILD.ArgentinaGILD.AustriaGILD.ItalyGILD34.BrazilGILD.SwitzerlandGILD.ChileGILD.Peru IPO Date
2008-05-07Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.19 | |||||
| Debt-to-EBITDA | 2.37 | |||||
| Interest Coverage | 13.66 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.59 | |||||
| Beneish M-Score | -2.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EBITDA Growth Rate | 5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -4.8 | |||||
| 3-Year FCF Growth Rate | 0.5 | |||||
| 3-Year Book Growth Rate | -1.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.37 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.28 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.87 | |||||
| 9-Day RSI | 33.25 | |||||
| 14-Day RSI | 38.62 | |||||
| 6-1 Month Momentum % | -12.04 | |||||
| 12-1 Month Momentum % | 2.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.91 | |||||
| Cash Ratio | 0.48 | |||||
| Days Inventory | 99.42 | |||||
| Days Sales Outstanding | 57.69 | |||||
| Days Payable | 43.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.14 | |||||
| Dividend Payout Ratio | 0.68 | |||||
| 3-Year Dividend Growth Rate | 5 | |||||
| Forward Dividend Yield % | 3.98 | |||||
| 5-Year Yield-on-Cost % | 5.86 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 5.89 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.42 | |||||
| Operating Margin % | 45.64 | |||||
| Net Margin % | 20.03 | |||||
| ROE % | 26.19 | |||||
| ROA % | 8.77 | |||||
| ROIC % | 17.51 | |||||
| ROC (Joel Greenblatt) % | 152.27 | |||||
| ROCE % | 16.05 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.37 | |||||
| Forward PE Ratio | 10.32 | |||||
| PE Ratio without NRI | 17.37 | |||||
| Shiller PE Ratio | 11.78 | |||||
| Price-to-Owner-Earnings | 15.98 | |||||
| PS Ratio | 3.48 | |||||
| PB Ratio | 4.45 | |||||
| Price-to-Free-Cash-Flow | 10.68 | |||||
| Price-to-Operating-Cash-Flow | 10.02 | |||||
| EV-to-EBIT | 13.64 | |||||
| EV-to-Forward-EBIT | 9.53 | |||||
| EV-to-EBITDA | 10.59 | |||||
| EV-to-Forward-EBITDA | 8.66 | |||||
| EV-to-Revenue | 4.12 | |||||
| EV-to-Forward-Revenue | 4.12 | |||||
| EV-to-FCF | 12.63 | |||||
| Price-to-Projected-FCF | 0.95 | |||||
| Price-to-Median-PS-Value | 0.91 | |||||
| Earnings Yield (Greenblatt) % | 7.33 | |||||
| Forward Rate of Return (Yacktman) % | 10.01 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gilead Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 516,838.528 | ||
| EPS (TTM) (MXN) | 83.018 | ||
| Beta | 0.05 | ||
| Volatility % | 27.66 | ||
| 14-Day RSI | 38.62 | ||
| 14-Day ATR (MXN) | 7.223684 | ||
| 20-Day SMA (MXN) | 1303.1 | ||
| 12-1 Month Momentum % | 2.11 | ||
| 52-Week Range (MXN) | 1230 - 1756 | ||
| Shares Outstanding (Mil) | 1,246.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gilead Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gilead Sciences Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gilead Sciences Inc Frequently Asked Questions
What is Gilead Sciences Inc(MEX:GILD)'s stock price today?
The current price of MEX:GILD is MXN1290.00. The 52 week high of MEX:GILD is MXN1756.00 and 52 week low is MXN1230.00.
When is next earnings date of Gilead Sciences Inc(MEX:GILD)?
The next earnings date of Gilead Sciences Inc(MEX:GILD) is 2023-10-27 Est..
Does Gilead Sciences Inc(MEX:GILD) pay dividends? If so, how much?
The Dividend Yield %  of Gilead Sciences Inc(MEX:GILD) is 4.14% (As of Today), Highest Dividend Payout Ratio of Gilead Sciences Inc(MEX:GILD) was 27.2. The lowest was 0.11. And the median was 0.58. The  Forward Dividend Yield % of Gilead Sciences Inc(MEX:GILD) is 3.98%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers